Two related reports describe mRNA vaccine strategies that improve antitumor immunity by changing how STING signaling is timed and activated. In Nature Biotechnology, a synchronized approach (Syn-STING) uses a lipid nanoparticle carrying multiple components designed to coordinate STING activation while preserving vaccine antigen production. Separate work reported in Nature Biotechnology also focuses on bioorthogonal-like delayed activation of exogenous STING, aiming to enhance mRNA vaccine efficacy. Together, the studies target the same problem: balancing innate immune stimulation against the risk that early signaling could interfere with antigen expression and downstream adaptive immunity. For drug developers, the message is that nanoparticle composition and activation kinetics may be as important as the choice of adjuvant target. Future translational impact will depend on whether these timing-based designs maintain benefit in human studies and do not introduce safety or manufacturing complexity that undermines scalability.